The formation of portal vein thrombosis (PVT) is one of the complications of liver cirrhosis, which is easily overlooked but is not uncommon. With the deepening research on PVT in liver cirrhosis, evidence regarding the assessment of PVT formation, treatment effectiveness, and prognostic outcomes is continually being updated. This article summarizes recent studies on predicting the formation, anticoagulation efficacy, and survival models; analyzes and evaluates the rationality, standardization, and practicality of prediction models; and compares their strengths and weaknesses to provide a reference for clinicians in the individualized management and treatment of PVT in patients with liver cirrhosis.

The formation of portal vein thrombosis (PVT) is one of the complications of liver cirrhosis, which is easily overlooked but is not uncommon. With the deepening research on PVT in liver cirrhosis, evidence regarding the assessment of PVT formation, treatment effectiveness, and prognostic outcomes is continually being updated. This article summarizes recent studies on predicting the formation, anticoagulation efficacy, and survival models; analyzes and evaluates the rationality, standardization, and practicality of prediction models; and compares their strengths and weaknesses to provide a reference for clinicians in the individualized management and treatment of PVT in patients with liver cirrhosis.

Liver failure is a kind of acute and severe liver disease.Bone marrow-derived mesenchymal stem cells(BM-MSCs)have the function of differentiating into hepatocytes.Promotion of the regeneration of hepatocytes re-generation,inhibition of apoptosis,necrosis and inflammation of hepatocytes,may facilitate repairing damaged liver tissue and improving liver function.BM-MSCs have become a new choice with great application potential in the treatment of liver failure.